CYP2D6*10 alleles do not determine plasma fluvoxamine concentration/dose ratio in Japanese subjects.
OBJECTIVE
The purpose of the present study was to investigate whether plasma fluvoxamine (FV) concentration is associated with CYP2D6*10 allele polymorphisms.


METHODS
Subjects were 46 Japanese patients (21 males) carrying neither *3, *4 nor *5 alleles and treated orally using FV. Venous blood was obtained from each patient for determination of FV concentration/dose (C/D) ratio (plasma concentration of FV divided by daily dose of FV per body weight) and CYP2D6 genotyping.


RESULTS
No significant differences in FV C/D ratio were found between subjects with no (n=13), one (n=18) or two (n=15) *10 alleles.


CONCLUSIONS
Our results indicate that CYP2D6*10 genotypes do not exert significant effects on FV C/D ratio. As CYP2D6 genotypes differ with ethnic background, further studies should be conducted in different populations.
Ohara
Koichi
K
Clinical Research Institute, National Minami Hanamaki Hospital, Hanamaki, Japan. kohara@shanamaki.hosp.go.jp
Tanabu
Shigeru
S
Ishibashi
Kazuhisa
K
Ikemoto
Keiko
K
Yoshida
Kimiko
K
Shibuya
Haruo
H
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000483:Alleles; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics* / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005260:Female; D016666:Fluvoxamine / Q000097:blood* / Q000493:pharmacokinetics; D005838:Genotype; D006801:Humans; D007564:Japan; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic; D017367:Selective Serotonin Reuptake Inhibitors / Q000097:blood* / Q000493:pharmacokinetics
D019389:Cytochrome P-450 CYP2D6; D016666:Fluvoxamine; D017367:Selective Serotonin Reuptake Inhibitors